

## With Cirrhosis

**TABLE 132: SVR GENOTYPE 3 WITH CIRRHOSIS TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.47 (1.14 to 1.79)	22.21 (6.77 to 36.34)
SOF12 + PR12		1.73 (1.09 to 2.09)	35.03 (4.28 to 49.96)
SOF12 + PR12	SOF24 + RBV24	1.17 (0.73 to 1.59)	12.27 (–20.27 to 34.04)
Random effect model	Residual deviance	7.854 vs. 8 data points	
	Deviance information criteria	48.042	
Fixed effect model	Residual deviance	8.366 vs. 8 data points	
	Deviance information criteria	48.013	

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.  
 Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.